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Abstract
Introduction: Several blood tests are performed uniformly in patients hospitalized with acute decompensated heart failure
and are predictive of the outcomes: complete blood count, electrolytes, renal function, glucose, albumin and uric acid. We
sought to evaluate the relationship between routine admission laboratory tests results, patient characteristics and 30-day
and one-year mortality of patients admitted for decompensated heart failure and to construct a simple mortality prediction
tool.
Methods: A retrospective population based study. Data from seven tertiary hospitals on all admissions with a principal
diagnosis of heart failure during the years 2002–2005 throughout Israel were captured.
Results: 8,246 patients were included in the study cohort. Thirty day mortality rate was 8.5% (701 patients) and one-year
mortality rate was 28.7% (2,365 patients). Addition of five routine laboratory tests results (albumin, sodium, blood urea, uric
acid and WBC) to a set of clinical and demographic characteristics improved c-statistics from 0.76 to 0.81 for 30-days and
from 0.72 to 0.76 for one-year mortality prediction (both p-values ,0.0001). Three dichotomized abnormal laboratory
results with highest odds ratio for one-year mortality (hypoalbuminaemia, hyponatremia and elevated blood urea) were
used to construct a simple prediction score, capable of discriminating from 1.1% to 21.4% in 30-day and from 11.6% to
55.6% in one-year mortality rates between patients with a score of 0 (1,477 patients) vs. score of 3 (544 patients).
Discussion: A small set of abnormal routine laboratory results upon admission can risk-stratify and independently predict
30-day and one-year mortality in patients hospitalized with acute decompensated heart failure.
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Introduction
Heart failure (HF) is a major worldwide public health concern.
Currently, more than 5 million people in the United States are
diagnosed with HF, and approximately 550,000 new cases are
reported annually with an estimated annual cost of $33.2
billion.[1]
Several blood tests are performed almost uniformly in patients
hospitalized with acute, decompensated heart failure: a complete
blood count, electrolytes levels, renal function, glucose, albumin
and uric acid levels. Anemia is a powerful independent predictor
of death and recurrent hospitalization in different subclasses of
HF.[2] Single measurement of the total white blood cells (WBC)
count is associated with all-cause and cardiovascular mortality in
clinically stable patients with left ventricular (LV) systolic
dysfunction.[3,4] Renal impairment is a frequent prognosticator
for mortality in patients hospitalized with HF.[5,6] Hyponatremia
and hyperkalemia are common in patients admitted with heart
failure and have been shown to predict mortality.[7,8,9,10] Uric
acid (UA) levels can be a marker of impaired prognosis in
hospitalized patients with acute HF and LV systolic dysfunc-
tion.[11,12] Low albumin concentration can be an indicator of
inflammation superimposed on cardiac cachexia – both factors
associated with increased mortality in populations with HF.[13,14]
Finally, high blood glucose levels are associated with worsening of
HF in diabetic and non-diabetic subjects.[15,16]
Lately numerous new biomarkers were evaluated as prognos-
ticators in HF population.[17,18,19] However, the limited
availability of these tests and lack of the standardization makes
their use problematic in day-to-day clinical practice. We
hypothesize that routine laboratory tests can be used for the same
purpose, i.e. prediction of outcome in patients hospitalized with
acute HF.
The purpose of this study was to construct and validate a
predictive tool for 30-day and one-year all cause mortality based
on a minimal set of admission routine laboratory tests together
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patients hospitalized for acute heart failure.
Methods
Ethics Statement
The study was a part of a quality control project. For the
purposes of the analysis deidentified database was created from the
hospitals administrative databases. Therefore no Ethics Commit-
tee approval or subject informed consent was needed.
All heart failure admissions to the seven major general hospitals
of the Clalit Health Services throughout Israel (30% of general
hospitals beds in the country) from November 2001 to June 2005
were screened. Each of the seven general hospitals transfers patient
level data to a central data warehouse, which is connected to the
computerized database of the Interior Ministry. The latter
provides real life information on the vital status of citizens.
Patients are identified in all databases by the unique national ID
number. The medical records of patients with primary discharge
diagnosis consistent with HF (International Classification of Diseases,
Ninth Revision code 428) and no concurrent myocardial infarction
were assessed electronically. For a sub-cohort of Clalit insured
patients (approximately 80% of the cohort), data on pre-
hospitalization medications were obtained.
We assessed the first available results of the laboratory test
performed within first 24 hours of admission. Based on predefined
definitions based on limits of normal range and the assessment of the
relationships between laboratory values and one-year mortality we
dichotomized the following variables: sodium (hyponatremia
,136 meq/L), urea (elevated $43 mg/dL), anemia (hematocrit
,40% in men and ,36% in women), albumin (low ,3.5 g/dL),
uric acid (elevated .6.5 mg/dL) and glucose (elevated$200 mg/
dL) and trichotomized white blood cells count (WBC leukocytosis
.10.8 10
3/mm
3, leucopenia,4.3 10
3/mm
3) and potassium
(hyperkalemia .5.0 meq/L, hypokalemia,3.5 meq/L). Glomeru-
lar filtration rate (GFR) was estimated based on the Modification of
Diet in Renal Disease (MDRD) Study equation and dichotomized
into two groups: $60 ml/min and ,60 ml/min. We used the
Charlson index to compute the burden of comorbid conditions.[20]
Statistical Analysis
The primary outcomes were 30-day and 1 year all cause deaths.
For univariate analysis, we used t-test for comparison of
continuous variables, and Pearson’s chi-square test for categorical
variables. Mann-Whitney test was used for comparison of variables
with non-normal distribution.
Risk prediction models were developed for 30-day and one-year
mortality. Since full follow-up was available on all participants and
primary interest was on event occurrence rather than its timing,
logistic regression was employed. Variable selection in multivar-
iable modeling was based on clinical and statistical significance
and performed in a hierarchical fashion, following the approach
outlined in.[21] In case of pair-wise correlations between
laboratory tests exceeding 0.50, we chose only one of those tests:
the one with stronger individual effect size (this led to selecting
urea over GFR and RBC over hematocrit).
First, all laboratory tests results significantly associated with one-
year mortality in univariate analysis were included into the
regression models for 30-day and one-year death as continuous
variables. Since WBC and potassium levels had non-linear
relationship with one-year mortality, those variables were included
in a categorical form (three groups): below low limit of normal,
normal (reference group) and above upper limit of normal.
Multiple partial tests were performed to confirm their significance
as a group. At the next step baseline clinical and demographic
characteristics: age, sex, history of myocardial infarction, dyslipi-
demia, arterial hypertension, diabetes, history of bypass surgery,
atrial fibrillation, chronic obstructive pulmonary disease, dementia
and Charlson index were added. Finally pre-hospitalization
medications were introduced: angiotensin-converting enzyme
inhibitors, angiotensin receptors blockers, b-blockers, statins,
spironolactone, digoxin and diuretics and tests of significance for
laboratory variables were repeated.
To investigate the most appropriate functional form (linear,
quadratic etc.) of the relationship between laboratory tests and
one-year mortality we fit generalized additive models which allow
for modeling the predictors as spline functions thus relaxing the
assumption of linearity (SAS proc GAM).[22] The results
confirmed those obtained by crudely plotting event rates across
sub-categories of laboratory tests.
Discriminatory abilities of the models were assessed by area
under the receiver operating characteristics (ROC) curves (AUC)
for death probability calculated for each subject. Discriminatory
abilities of the models were compared using a test for difference of
two AUCs proposed by DeLong et al. and available through the
roccontrast option in SAS proc logistic. [23] Calibration of the
models was evaluated by Hosmer and Lemeshow chi-square test of
goodness of fit. For model derivation we randomly selected 3 out
of 7 hospitals. Once the models were derived and shown to be
valid in the other 4 hospitals, the two cohorts (derivation and
validation) were combined for further analysis.
To further evaluate the models’ performance the echocardiog-
raphy data obtained within 63 month from the index hospital-
ization for 854 subjects admitted to one of the hospital were
assessed. Ejection fraction and presence of diastolic dysfunction
were included into the models predicting 30-day and 1 year
mortality and c-statistics were calculated.
To simplify clinical application the final model was repeated
with significant laboratory test results dichotomized or trichoto-
mized as described earlier and three of those variables with the
highest odds ratios for one-year mortality were selected for
inclusion into the clinical score. We assigned 1 point for each
pathological result. Combined score was calculated for each
patient. Kaplan-Meier analysis with log-rank test was used for
assessing the relationship between the combined score and one-
year mortality. All reported P values are two-sided and p,0.05
was considered significant.
Results
Study population
During 44 months of the study 15,661 admissions to seven
hospitals with a principal diagnosis of heart failure decompensa-
tion were recorded 45.2% of which were repeat admissions.
Overall 8,246 patients with a first HF admission during the study
period comprised the study cohort. Median hospitalization
duration was 4 days (interquartile range [IQR] of 2 to 7 days).
During the hospital stay 467 patients (5.7%) died. Thirty day
mortality rate was 8.5% (701 patients) and one-year mortality rate
was 28.7% (2,365 patients).
Table 1 depicts baseline characteristics of the patient population
stratified by one-year mortality. The deceased patients compared
with the one year survivors were older (79.4%610.9% vs.
74.0%611.8%; p,0.001), and had more comorbidities as
indicated by higher Charlson Comorbidity index (5.3%61.8%
vs. 4.3%61.7%;p,0.001). Although the deceased patients had
lower prevalence of diabetes mellitus (35.3% vs. 39.5%; p,0.001),
hypertension (53.6% vs. 61.2%; p,0.001), dyslipidemia (18.6% vs.
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HF Mortality Prediction29.1%;p,0.001) and previous CABG surgery (13.8% vs. 17.6%),
they had higher prevalence of atrial fibrillation (40.3% vs. 34.2%),
valvular diseases (15.0% vs. 11.1%), acute and chronic renal
failure (8.2% vs. 3.3% and 21.4% vs. 11.8% respectively), anemia
(27.6% vs. 22.0%), pleural effusion or ascites (10.3% vs. 7.0%),
chronic obstructive pulmonary disease (16.8% vs.13.2%) and
much higher prevalence of dementia (9.4% vs. 2.9%, all with p-
value ,0.001). Of note, survivors had higher rates of life saving
cardiac medications use, such as ACE inhibitors (10.1% vs. 7.1%),
b-blockers (59.1% vs.50.0%), statins (42.7% vs. 29.8%) and
aspirin(54.1% vs.48.7%) but lower rates of spironolacton (18.4%
vs. 23.4%) and diuretics use(73.9% vs. 78.8%, all with p-value
,0.001). All laboratory values at admission (except glucose levels)
were significantly different between survivors and deceased.
Laboratory analysis (Table 2)
During the first 24 hours of admission sodium levels were
available for 7,963 patients (96.6%,) and potassium in 7,601
(92.2%, Figure 1, Figure 2). Hyponatremia was found in 1755
patients (22.0%) and 1,428 (14.8%) had hyperkalemia. One-year
crude relative risk (RR) of death in patients with hyponatremia at
admission was 1.54 (95%CI 1.43–1.66) and 1.40 (95%CI 1.29–
1.52) for hyperkalemia.
Hematocrit results were available in 8,047 patients (97.6%).
Anemia was found in 57.1% of the patients and was more frequent
among males: 63.7% vs. 49.9% in female patients, p,0.001.
Patients with anemia had a one-year mortality RR=1.24 (95%CI
1.17–1.34) as compared to non-anemic group. White blood count
was available in 8,064 cases (97.8%). Leukocytosis was found in
26.8% of the patients and was associated with one-year death:
RR=1.29 (95%CI 1.20–1.38).
Serum createnine results were available for 8,038 patients
(97.5%). GFR less than 60 ml/min was found in 84.2%, while
25.2% of the patients had GFR,30 ml/min. Patients with
GFR,30 ml/min had higher one-year mortality risk: RR=1.62
(95%CI 1.51–1.73). Blood urea results were available in 8,034
Table 1. Baseline characteristics of the patient population.
All patients One-year survivors Deceased p-value
N=8,246 N=5,881 N=2,365
Age, year 75.6611.8 74.0611.8 79.4610.9 ,0.001
Gender, female (%) 47.8 47.1 49.6 0.04
Charlson score, (points) 4.661.8 4.361.7 5.361.8 ,0.001
Co-morbidities
Ischemic heart disease, (%) 60.8 61.4 59.4 0.10
Previous myocardial infarction, (%) 24.2 24.2 24.4 0.84
Diabetes, (%) 38.3 39.5 35.3 ,0.001
Arterial hypertension, (%) 59.0 61.2 53.6 ,0.001
Dyslipidemia, (%) 26.1 29.1 18.6 ,0.001
Atrial fibrillation, (%) 35.9 34.2 40.3 ,0.001
Non ischemic cardiomyopathy, (%) 4.1 4.2 3.7 0.25
Previous CABG, (%) 16.5 17.6 13.8 ,0.001
Previous valvular surgery, (%) 3.3 3.4 3.1 0.49
Any valvular disease, (%) 27.7 27.5 28.2 0.47
Aortic valve disease, (%) 12.2 11.1 15.0 ,0.001
Mitral valve disease, (%) 18.5 19.1 17.1 0.03
Chronic renal failure, (%) 14.5 11.8 21.4 ,0.001
Acute renal failure, (%) 4.8 3.3 8.2 ,0.001
Anemia, (%) 23.6 22.0 27.6 ,0.001
Pleural effusion or ascites, (%) 7.9 7.0 10.3 ,0.001
Chronic obstructive pulmonary disease, (%) 14.2 13.2 16.8 ,0.001
Dementia, (%) 4.7 2.9 9.4 ,0.001
Medications at 3 months prior to hospitalization (n=7,105)
Angiotensin-converting enzyme inhibitors, (%) 59.9 60.6 58.0 0.04
Angiotensin receptor blockers, (%) 9.3 10.1 7.1 ,0.001
Aspirin, (%) 52.5 54.1 48.7 ,0.001
b-blockers, (%) 56.5 59.1 50.0 ,0.001
Statins, (%) 39.0 42.7 29.8 ,0.001
Spironolactone, (%) 19.8 18.4 23.4 ,0.001
Digoxin, (%) 15.1 14.6 16.4 0.05
Diuretics, (%) 75.3 73.9 78.8 ,0.001
doi:10.1371/journal.pone.0012184.t001
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associated with one-year mortality: RR=2.26 (95%CI 1.90–2.26).
Hypoalbuminemia was found in 36.3% out of 7,775 tested
patients and was associated with one-year mortality: RR=1.85
(95%CI 1.72–1.98). Uric acid levels were available in 6,755
patients (81.9%). An elevated level of uric acid was associated with
one-year mortality: RR=1.42 (95%CI 1.30–1.56).
Glucose results were available for 8,028 patients (97.4%) and 1,897
(23.6%) had levels above 200 mg/dL. There was no association
between glucose.200 mg/dL and one-year mortality neither in
Table 2. Baseline laboratory characteristics of the patient population.
All patients One-year survivors Deceased p-value
N=8,246 N=5,881 N=2,365
Laboratory values at admission
Hematocrit, % (n=8,047) 37.165.7 37.565.7 36.265.8 ,0.001
RBC, 10
3/mm
3 (n=8,065) 4.2960.71 4.3560.69 4.1560.73 ,0.001
WBC, 10
3/mm
3 (n=8,064) 9.864.6 9.564.1 10.365.5 ,0.001
Blood urea, (n=8,034) 62.7637.4 56.5631.6 78.0645.5 ,0.001
Glomerular filtration rate, ml/min (n=7,685) 42.3619.0 44.6618.6 36.8618.6 ,0.001
Sodium, mEq/L (n=7,963) 137.364.8 137.664.5 136.465.3 ,0.001
Potassium, mEq/L (n=7,601) 4.560.7 4.560.6 4.660.8 ,0.001
Albumin, g/dL (n=7,775) 3.660.5 3.760.5 3.460.5 ,0.001
Glucose, mg/dL (n=8,028) 162.7680.6 162.2679.4 164.0683.3 0.38
Uric acid, mg/dL (n=6,755) 8.062.6 7.762.3 8.863.0 ,0.001
doi:10.1371/journal.pone.0012184.t002
Figure 1. Results of the laboratory tests and one year mortality rates. Three laboratory tests with abnormal results associated with one-year
mortality and highest odds ratio (albumin, sodium and urea).
doi:10.1371/journal.pone.0012184.g001
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(27.3%hadglucose.200 mg/dL):p=0.49 and p=0.17 respectively.
Multivariable Analysis
Five laboratory test results: albumin, sodium, blood urea, uric
acid and WBC were significantly related to 30-day and one-year
mortality, as a group and individually, in unadjusted models as well
as in models that adjusted for baseline clinical and demographic
characteristics and for baseline medications. Corresponding odds
ratios per one standard deviation increase are presented in Table 3.
Generalized additive models revealed no meaningful departures
from linearityforthelaboratoryvariables.Hence,nonew cut-points
Figure 2. Results of the laboratory tests and one year mortality rates. Three laboratory tests with abnormal results associated with one-year
mortality and lowest odds ratio (uric acid, potassium and leukocytosis).
doi:10.1371/journal.pone.0012184.g002
Table 3. Odds ratios* for five laboratory values calculated per standard deviation for sodium, blood urea, albumin and uric acid
and for leucopenia and leukocytosis for WBC.
One-year mortality 30-day mortality
95% Confidence Interval 95% Confidence Interval
Odds ratio Lower limit Upper limit Odds ratio Lower limit Upper limit
Sodium 0.80 0.75 0.85 0.84 0.77 0.92
Blood urea 1.42 1.32 1.52 1.46 1.33 1.59
Albumin 0.64 0.60 0.69 0.63 0.57 0.69
WBC, normal range Referent =1.00
WBC,4,300 10
3/mm
3 1.33 0.91 1.96 1.19 0.63 2.24
WBC.10,800 10
3/mm
3 1.23 1.08 1.41 1.60 1.31 1.96
Uric acid 1.31 1.23 1.40 1.31 1.19 1.44
*odds ratios expressed per one standard deviation increase in laboratory test level except for WBC which compares abnormal values to a reference group.
Derived from 30-day and one-year mortality prediction logistic regression models inclusive of laboratory tests, demographics and comorbidities.
doi:10.1371/journal.pone.0012184.t003
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values dichotomized using standard cut-points.
Discriminative and calibration abilities of the models for
30-day and one-year mortality prediction
C-statistics in the derivation cohort (3 hospitals, 3,941 subjects)
and the validation cohort (4 hospitals, 4,305 subjects) were similar
for all models and hence we decided to pool them and present
results on combined data for increased precision. Table 4 presents
the discriminative characteristics and calibration results for
different combinations of variable groups (demographics, comor-
bidities, laboratory results and pre-hospitalization medications).
Addition of the 5 laboratory test results to a model with baseline
clinical and demographic characteristics increased the c statistic
from 0.72 to 0.81 for 30-day mortality model and from 0.69 to
0.76 for one-year mortality model with both increases highly
statistically significant (both p-values ,0.0001). Figure 5 presents
the calibration plot for the full model for 30-day and 1 year
mortality prediction.
Using the maximum sum of sensitivity and specificity as a rule
to obtain the best cut-off point for classification we arrived at the
following results:
For 1 year mortality the classification threshold was 0.28 with a
sensitivity of 68.8% and specificity of 72.7%. Observed mortality
rate for subjects classified as high risk was 48.2% (predicted
mortality47.7%) and aslowrisk 14.8%(predictedmortality15.2%).
Figure 3. Odds ratios of laboratory values for 30-day all cause mortality. Five categorized laboratory tests found to be significant in the
multivariable analysis as continuous variables are presented.
doi:10.1371/journal.pone.0012184.g003
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sensitivity of 73.1%% and specificity of 70.1%. Observed mortality
rate for subjects classified as high risk was: 19.5% (predicted
mortality 18.8%) and as low risk 3.0% (predicted mortality 3.3%).
Echocardiography results
We included echocardiography data obtained within 63 month
from the index hospitalization for 854 subjects admitted to one of
the hospitals. Severe systolic dysfunction (ejection fraction,30%)
was found in 41.2% and diastolic dysfunction was diagnosed in
35.3% of the patients. Ejection fraction and diastolic dysfunction
were added to demographic characteristics and comorbidities
variables group. Inclusion of echocardiography results did not
change the overall discriminative ability of the models or
calibration: neither for 30-day, nor for one-year mortality
prediction.
Simplified clinical score
A simplified version of the clinical prediction score based on
three dichotomized abnormal laboratory results (blood albumin,
sodium and urea, available for 7,608 patients, 92.3%) was
developed. One-year logistic regression model inclusive of uremia,
Figure 4. Odds ratios of laboratory values for one-year all cause mortality. Five categorized laboratory tests found to be significant in the
multivariable analysis as continuous variables are presented.
doi:10.1371/journal.pone.0012184.g004
HF Mortality Prediction
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ties yielded the following odds ratios: uremia 1.50; hypoalbumin-
emia 1.73 and hyponatremia 1.63. Since the odds ratios were
similar, each abnormal result was assigned 1 point. The score
ranged from 0 points (1,300 patients, 17.1%), 1 point (3,397
patients, 44.7%), 2 points (2,338 patients, 30.7%) to 3 points (573
patients, 7.5%) and was capable of discriminating from 1.4% to
20.2% in 30-day mortality and 11.2% to 55.0% in one-year
mortality rates between patients with a score of 0 to 3. Table 5
shows that mortality risk at 30-day and one-year were similar
across the entire spectrum of risk between derivation and
validation cohorts.
Missing score rates were distributed evenly between the
hospitals being less than 10% in each one of them (in total
missing in 7.7% patients). Thirty day mortality was slightly higher
in group of patients with missing score (10.5% vs. 8.3%) while 1-
year mortality was slightly lower (27.7% vs. 28.8%).
Length of the hospitalization increased with higher score: from
a median of 3 days (IQR 2–5) in group of patients with score of 0,
4 days (IQR 2–6) in score 1, 4 days (IQR 3–8) in score 2 and 5
days (IQR 3–10) in patients with score 3, p,0.001 for trend.
Kaplan-Meier analysis (figure 6) showed that assignment of the
risk score at baseline maintained the prognostic implication at all
time point up to 1 year (log-rank test p,0.001).
Discussion
Assessing the prognosis of HF patients at admission is essential
for several reasons. It can help determine the intensity of initial
treatment and monitoring, facilitate triage decisions, provide initial
information to patients and relatives, and is also important for
audit and retrospective quality control.
We found that the addition of readily available laboratory tests
improve significantly the predictive ability of the survival models
based on clinical and demographic characteristics. A few routine
test results (albumin, urea, WBC, uric acid and sodium) have a
discriminative ability for 30-day and one-year mortality predic-
tions comparable with more sophisticated and expensive biomark-
ers such as BNP, NT-proBNP, H-FABP, Mid-Regional pro-
Adrenomedullin (MR-proADM) and PTX3.[17,18,19]
Several scores were proposed for predicting survival in these
patients, but they vary in the choice, extent and availability of the
required components. Lee et al [24] developed a score composed
of eleven variables, including demographic characteristics, co-
morbid conditions, clinical signs and selected laboratory values
obtained within twenty four hours of admission. The overall
prediction accuracy for this score is similar to the discriminative
power of our full models (demographic characteristics, comorbid-
ities and laboratory tests results): c-statistics for 30-days 0.79 vs.
0.81 and for one-year mortality 0.76 vs. 0.76 respectively.
However, it requires data on vital signs such as blood pressure
and respiratory rates. The Heart Failure Survival Score [HFSS]
requires more elaborate calculation and stratifies patients with
NYHA class III and IV based on history, heart rate, LVEF, BP,
IVCD, sodium and peak VO2.[25] More recently, The Seattle
Heart Failure Model was developed which uses a combination of
history, ejection fraction, BP, medication use and laboratory
values to predict survival for ambulatory and hospitalized patients
with HF.[26] Using the ADHERE registry, Fonarow et al. was
able to risk stratify patients into low, intermediate and high risk
representing a 2–22% range for in hospital mortality using levels
of urea, createnine and SBP with an area under the curve of
0.67–0.69. [27]
As there is a clear trade-off between the simplicity and ease of
use of available prediction tools and the accuracy of prediction, the
challenge is to choose an optimal tool for the task. Three of the
easily obtainable routine admission tests (albumin, sodium and
urea) can constitute a simple prognostic score with one point
assigned for each abnormal result. This score was able to risk
stratify 30-day mortality with a range of 1%–21% and one-year
mortality in a range of 12–56%. Compared with the full model
and other similar survival prediction tools this short score, based
on the standard cut-off point for the normal range of the routine
laboratory tests, allows for rapid implementation on the level of the
treating physician. Its simplicity eliminates the need for elaborate
calculations requiring bed-side computers or memorization of the
different schemes for the score point assignment.
Our study does not necessarily present new information on the
potential mortality predictors in patients with acute decompen-
sated heart failure. Rather we have shown that the use of simple
and relatively inexpensive laboratory tests may achieve the same
degree of accuracy in predicting the outcomes as more
contemporary and sophisticated biomarkers. One can assume
that the biomarkers are not independent from the patient’s clinical
condition. The severity of the disease can be evident by analyzing
Table 4. Calibration and Discrimination of the logistic regression models.
Demographics and
comorbidities only Laboratory tests only
Laboratory tests,
demographics and
comorbidities
Laboratory tests,
demographics, comorbidities
and pre-hospitalization
medications*
c-statistics
Calibration
chi-square
and p-value c-statistics
Calibration
chi-square
and p-value c-statistics
Calibration
chi-square
and p-value c-statistics
Calibration
chi-square
and p-value
30-day
mortality
0.72 6.02 0.76 4.81 0.81
11.82 0.82 10.19
p-value/C.I. (0.70–0.74) 0.65 (0.74–0.78) 0.78 (0.79–0.83) 0.16 (0.78–0.84) 0.25
One-year
mortality
0.69 7.63 0.72 9.78 0.76
6.61 0.77 4.35
p-value/C.I. (0.68–0.70) 0.47 (0.71–0.74) 0.28 (0.75–0.78) 0.58 (0.73–0.79) 0.82
*-adjusted for pre-hospitalization use of angiotensin-converting enzyme inhibitors, angiotensin receptors blockers, b-blockers, statins, spironolactone, digoxin and
diuretics.
Laboratory tests include albumin, urea, sodium, uric acid and WBC.
doi:10.1371/journal.pone.0012184.t004
HF Mortality Prediction
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doi:10.1371/journal.pone.0012184.g005
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laboratory tests. The added value of the individual test is usually
small (though sometimes important); therefore the approach based
on the entire clinical picture might provide a greater insight into
the individual patient prognosis. Moreover, the likelihood of
survival can be determined reliably only in populations and not in
individuals.[28]
Our study has a number of limitations. We did not have a direct
comparison to discriminative abilities of more novel biomarkers
such as BNP/NT-proBNP. BNP/NT-proBNP have been shown
to be predictive of mortality in several studies of HF, however
these tests are not routinely available in many countries and add
significantly to laboratory costs.[27,29] The study was only
performed in one country; however the care of patients with HF
in Israel has been shown to be similar to that of European and
North American countries.[30] Patients included in this retro-
spective study were those with a discharge diagnosis of HF as
recorded by the treating physicians and coded with ICD-9
classification without consistent capturing of patients’ functional
status (NYHA class). We were not able to separate between the
first incidence of HF admission in life and repeated admission. It
might be expected that repeated admission patients have different
prognosis. Our analysis included data from the hospitals operating
under the centrally managed universal health system (Clalit Health
Services), therefore it might be expected that the models will
perform differently in other countries. Lastly, although the
participating hospitals belong to the same health care system,
some variations in laboratory measurements might exist.
The strength of our study is the large number of consecutive,
non-selected patients studied and the applicability of the score to
all patients presenting to the hospital with a diagnosis of HF. In
addition we had the complete follow-up data on long term
mortality. Our analysis shows that based on the administrative
data analysis (patient demographics, recorded diagnosis and
number of laboratory tests results) the reasonable degree of the
prognostication can be achieved.
In summary, we have confirmed that a number of demographic
characteristics, comorbidities and abnormal laboratory tests are
predictive of 30-day and one-year mortality in patients admitted
Table 5. Mortality rates stratified by the score.
Score
0 points 1 point 2 points 3 points
30-day
mortality rate
derivation
cohort 1.0% 5.1% 13.0% 17.8%
validation
cohort 1.7% 6.7% 13.5% 23.4%
1-year
mortality rate
derivation
cohort 11.2% 23.6% 39.9% 55.3%
validation
cohort 12.0% 25.0% 40.0% 55.9%
For each abnormal result in admission laboratory test (urea$43 mg/dL,
sodium,136 meq/L and albumin,3.5 g/dL) one point was assigned. Patient
population was stratified by the total combined score. Mortality rates presented
for derivation cohort (3 hospitals, 3,941 subjects) and validation cohort
(4 hospitals, 4,305 subjects).
doi:10.1371/journal.pone.0012184.t005
Figure 6. Kaplan-Meier curves for one-year mortality according to risk points. For each abnormal result in admission laboratory test
(urea$43 mg/dL, sodium,136 meq/L and albumin,3.5 g/dL) one point was assigned. Patient population was stratified by the total combined
score. Log-rank test, p,0.001.
doi:10.1371/journal.pone.0012184.g006
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laboratory tests can help risk-stratify patients with HF. These
results need to be prospectively confirmed in other cohorts of HF
patients.
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